Difference between revisions of "Cerwenka A, et al, J Exp Med (1999), cited as Ref 36 in DOI:10.1007/s11886-020-01292-3 (Q10545)"
Jump to navigation
Jump to search
(Created claim: Second Author string (P150): Morgan TM, #quickstatements; #temporary_batch_1592502960189) |
(Created claim: Third Author string (P151): Harmsen AG, #quickstatements; #temporary_batch_1592503188634) |
||
| Property / Third Author string | |||
| + | Harmsen AG | ||
| Property / Third Author string: Harmsen AG / rank | |||
| + | Normal rank | ||
Revision as of 18:00, 18 June 2020
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Cerwenka A, et al, J Exp Med (1999), cited as Ref 36 in DOI:10.1007/s11886-020-01292-3
|
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
|
Statements
Q10356 (Deleted Item)
0 references
Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection (English)
0 references
Cerwenka A
0 references
Morgan TM
0 references
Harmsen AG
0 references
